

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



VLL\SE\039\2023-24
Date: 25.07.2023

Listing Centre
B S E Limited
P J Towers, Dalal Street
Mumbai: 400001
Scrip Code No.524394

Asst Vice President
National Stock Exchange of India Limited
"Exchange Plaza", Bandra
Kurla Complex, Bandra (E)
Mumbai – 400051
Trading Symbol: VIMTALABS

Dear Sirs,

Sub: Allotment of Employee Stock Options under "Vimta Labs Employee Stock Option Plan 2021"

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the ESOP Allotment Committee of the Board of Directors of the Company at their meeting held on **25th July 2023 has allotted 4530 equity shares of face value of Rs.2/- each**, to the eligible employees of the Company under Vimta Labs Employee Stock Option Plan 2021.

The paid-up share capital of the Company has accordingly increased from Rs. 4,42,77,098 consisting of 2,21,38,549 equity shares having a face value of Rs. 2/- each to **Rs. 4,42,86,158** consisting of **2,21,43,079** equity shares having a face value of Rs. 2/- each.

Further, we would like to confirm that the above allotted shares shall rank pari-passu with the existing equity shares of the Company and the Company is in the process of completing the other formalities with respect to listing of the said allotted shares.

The details as required as disclosure under Part E, Regulation 10(c) of SEBI ESOP Regulations are enclosed as "Annexure-A".

This is for your information and records.

Thanking you,

Yours faithfully,
for VIMTA LABS LIMITED

Sujani Vasireddi
Company Secretary



Page 1 of 2

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657

**Annexure-A****Disclosure under Part E pursuant to Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021**

Sl. No.	Particulars	Details
1	Company name and address of Registered Office :	Vimta Labs Limited Plot No. 142, IDA, Phase-II, Cherlapally, Hyderabad, Telangana – 500051
2	Name of the recognised Stock Exchanges on which the company's shares are listed	BSE Limited National Stock Exchange of India Limited
3	Filing date of the statement referred in regulation 10(b) of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognized Stock Exchange	Filing date: 28.07.2021; The Company had received consolidated 'in-principle' listing approval from BSE vide letter dated 15.09.2021 for 6,63,234 equity shares. Filing date: 28.07.2021; The Company had received consolidated 'in-principle' listing approval from NSE vide letter dated 06.08.2021 for 6,63,234 equity shares .
4	Filing Number, if any	BSE: DCS/FL/MJ/ESOP-IP/1472/2021-22 NSE: NSE/LIST/27779
5	Title of the Scheme pursuant to which shares are issued, if any:	Vimta Labs Employee Stock Option Plan 2021
6	Kind of security to be listed	Equity Shares
7	Par value of the shares	Rs.2/-
8	Date of issue of shares	25th July 2023
9	Number of shares issued	4530
10	Share Certificate No., if applicable	Not Applicable.
11	Distinctive number of the share, if applicable:	25838550-25843079 (Both Inclusive)
12	ISIN Number of the shares if issued in Demat	INE579C01029
13	Exercise price per share	2/-
14	Premium per share	Not Applicable.
15	Total Issued shares after this issue	2,21,43,079
16	Total issued share capital after this issue	Rs. 4,42,86,158
17	Details of any lock-in on the shares	Not Applicable
18	Date of expiry of lock-in	Not Applicable
19	Whether shares are identical in all respects to existing shares? If not, when will they become identical?	All equity shares of the Company allotted pursuant to exercise of stock options shall rank pari-passu with the existing equity shares of the Company.
20	Details of listing fees, if payable	Not Applicable



Page 2 of 2